查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553471

僵直性脊椎炎市场规模、份额、趋势分析报告：按药物类别、分销管道、地区、细分市场预测，2024-2030 年

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-steroidal Anti Inflammatory, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

僵直性脊椎炎市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球僵直性脊椎炎市场规模将达到91.2亿美元，2024年至2030年复合年增长率为6.4%。

强大产品平臺的存在可能会加速市场成长。例如，UCB SA的研发线产品bimekizumab在2B期试验中显示出正面的结果，使其成为预测期内推向市场的潜在候选药物。

製药公司的目标是扩大标籤和专利范围，以维持市场份额。 2017 年 10 月，强生服务公司的 AS 治疗药物Simponi获得核准，用于治疗活动性干癣性关节炎(PsA) 或活动性僵直性脊椎炎(AS)。这些治疗领域的进步预计将对市场成长产生积极影响。

此外，有利的报销政策的存在也有望促进成长。例如，在加拿大（安大略省）公共药物计划中，诺华宣布报销 Cosentyx 用于治疗强直性强直。根据诺华公司发表的一篇论文，大约 20% 至 40% 的患者在使用抗 TNF 药物后没有获得足够的临床改善。

僵直性脊椎炎市场报告亮点

  • TNF（肿瘤坏死因子）细分市场占据主导地位，2023 年销售份额为 59.4%。 TNF 抑制剂以肿瘤坏死因子为标靶来治疗类风湿性关节炎等自体免疫疾病，预计将显着增长。
  • 预计非类固醇消炎剂(NSAID) 市场在预测期内将以 8.8% 的复合年增长率成长。
  • 北美僵直性脊椎炎市场2023年占最大销售份额，达57.9%。
  • 主要企业正在采取产品开拓、併购和区域扩张等策略来增加市场占有率。
  • 例如，2019年1月，三星Bioepis有限公司宣布与三生製药建立策略伙伴关係，以扩大产品系列。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章全球僵直性脊椎炎市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 全球僵直性脊椎炎市场分析工具
    • 波特的分析
    • PESTEL分析

第四章全球僵直性脊椎炎市场：药物类别估计与趋势分析

  • 细分仪表板
  • 全球僵直性脊椎炎市场：药物类别变化分析（百万美元），2023-2030 年
  • 非类固醇消炎剂(NSAID)
  • 肿瘤坏死因子抑制剂
  • 其他药物类别

第五章全球僵直性脊椎炎市场：通路估算及趋势分析

  • 细分仪表板
  • 全球僵直性脊椎炎市场：分销管道波动分析，百万美元，2023-2030
  • 医院药房
  • 零售药房
  • 其他的

第六章全球僵直性脊椎炎市场：区域估计与趋势分析

  • 全球僵直性脊椎炎市场占有率（按地区），2023 年和 2030 年，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第七章 竞争格局

  • 最新趋势与影响分析：主要市场参与企业
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • AbbiVie, Inc
    • Amgen, Inc.
    • Pfizer, Inc.
    • UCB, Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Johnson and Johnson Services, Inc.
    • Merck and Co., Inc.
简介目录
Product Code: GVR-4-68038-728-5

Ankylosing Spondylitis Market Growth & Trends:

The global ankylosing spondylitis market size is expected to reach USD 9.12 billion by 2030, registering a CAGR of 6.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province's public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

Ankylosing Spondylitis Market Report Highlights:

  • The TNF (Tumor Necrosis Factor) segment dominated the market and accounted for a revenue share of 59.4% in 2023. TNF inhibitors, which target tumor necrosis factors to manage autoimmune conditions such as rheumatoid arthritis, are anticipated to experience significant growth.
  • The Non-steroidal Anti-Inflammatory Drug (NSAID) market is expected to grow at a CAGR of 8.8% over the forecast years.
  • The North America ankylosing spondylitis market accounted for the largest revenue share of 57.9% in 2023
  • Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share
  • For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Ankylosing Spondylitis Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Ankylosing Spondylitis Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Ankylosing Spondylitis Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Ankylosing Spondylitis Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
    • 4.3.1. Non-Steroidal Anti-Inflammatory Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. TNF Inhibitors
    • 4.4.1. TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Humira
      • 4.4.2.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Simponi
      • 4.4.3.1. Simponi Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Remicade
      • 4.4.4.1. Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Enbrel
      • 4.4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Cimzia
      • 4.4.6.1. Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.7. Other TNF Inhibitors
      • 4.4.7.1. Other TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Other Drug Classes
    • 4.5.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Ankylosing Spondylitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Ankylosing Spondylitis Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Hospital Pharmacy
    • 5.3.1. Hospital pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Retail Pharmacy
    • 5.4.1. Retail pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis

  • 6.1. Global Ankylosing Spondylitis Market Share, By Region, 2023 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Global Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. AbbiVie, Inc
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Amgen, Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Pfizer, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. UCB, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Novartis AG
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Eli Lilly and Company
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Johnson and Johnson Services, Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck and Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives